Literature DB >> 21148271

URAT1 mutations cause renal hypouricemia type 1 in Iraqi Jews.

Dganit Dinour1, Andrew Bahn, Liat Ganon, Rotem Ron, Ossie Geifman-Holtzman, Aaron Knecht, Uzi Gafter, Ruth Rachamimov, Ben-Ami Sela, Gerhard Burckhardt, Eliezer J Holtzman.   

Abstract

BACKGROUND: Hereditary renal hypouricemia may be complicated by nephrolithiasis or exercise-induced acute renal failure. Most patients described so far are of Japanese origin and carry the truncating mutation W258X in the uric acid transporter URAT1 encoded by SLC22A12. Recently, we described severe renal hypouricemia in Israeli patients with uric acid transporter GLUT9 (SLC2A9) loss-of-function mutations. Renal hypouricemia in Iraqi Jews has been previously reported, but its molecular basis has not been ascertained.
METHODS: Three Jewish Israeli families of Iraqi origin with hereditary hypouricemia and hyperuricosuria were clinically characterized. DNA was extracted and the URAT1 gene was sequenced. Transport studies into Xenopus laevis oocytes were utilized to evaluate the function of URAT1 mutants found.
RESULTS: A missense URAT1 mutation, R406C, was detected in all three families. Two affected siblings were found to carry in addition a homozygous missense URAT1 mutation, G444R. Both mutations dramatically impaired urate uptake into X. laevis oocytes. Moreover, we demonstrate for the first time that URAT1 facilitates urate efflux, which was abolished in the mutants, indicating also a secretion defect. Homozygous patients had serum uric acid concentrations of 0.5-0.8 mg% and a fractional excretion of uric acid of 50-85%. Most individuals studied were asymptomatic, two had nephrolithiasis and none developed exercise-induced acute renal failure.
CONCLUSIONS: The URAT1 R406C mutation detected in all three families is likely to be the founder mutation in Iraqi Jews. Our findings contribute to a better definition of the different types of hereditary renal hypouricemia and suggest that the phenotype of this disorder depends mainly on the degree of inhibition of uric acid transport.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148271     DOI: 10.1093/ndt/gfq722

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  20 in total

Review 1.  Genetics of hyperuricemia and gout: implications for the present and future.

Authors:  Ronald L George; Robert T Keenan
Journal:  Curr Rheumatol Rep       Date:  2013-02       Impact factor: 4.592

Review 2.  Targeting urate to reduce oxidative stress in Parkinson disease.

Authors:  Grace F Crotty; Alberto Ascherio; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2017-06-13       Impact factor: 5.330

Review 3.  Regulation of uric acid excretion by the kidney.

Authors:  Michael S Lipkowitz
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

4.  Novel allelic variants and evidence for a prevalent mutation in URAT1 causing renal hypouricemia: biochemical, genetics and functional analysis.

Authors:  Blanka Stiburkova; Ivan Sebesta; Kimiyoshi Ichida; Makiko Nakamura; Helena Hulkova; Vladimir Krylov; Lenka Kryspinova; Helena Jahnova
Journal:  Eur J Hum Genet       Date:  2013-02-06       Impact factor: 4.246

5.  Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2.

Authors:  Andrea Mancikova; Vladimir Krylov; Olha Hurba; Ivan Sebesta; Makiko Nakamura; Kimiyoshi Ichida; Blanka Stiburkova
Journal:  Clin Exp Nephrol       Date:  2015-10-24       Impact factor: 2.801

6.  Clinical and functional characterization of URAT1 variants.

Authors:  Velibor Tasic; Ann Marie Hynes; Kenichiro Kitamura; Hae Il Cheong; Vladimir J Lozanovski; Zoran Gucev; Promsuk Jutabha; Naohiko Anzai; John A Sayer
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

7.  Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials.

Authors:  Robert A Yood; Faith D Ottery; William Irish; Marsha Wolfson
Journal:  BMC Res Notes       Date:  2014-01-21

8.  Transcriptome-based reconstructions from the murine knockout suggest involvement of the urate transporter, URAT1 (slc22a12), in novel metabolic pathways.

Authors:  Satish A Eraly; Henry C Liu; Neema Jamshidi; Sanjay K Nigam
Journal:  Biochem Biophys Rep       Date:  2015-09-01

Review 9.  The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality.

Authors:  David Gustafsson; Robert Unwin
Journal:  BMC Nephrol       Date:  2013-07-29       Impact factor: 2.388

10.  A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.

Authors:  Jacob Leander; Mikael Sunnåker; Dinko Rekić; Sergey Aksenov; Ulf G Eriksson; Susanne Johansson; Joanna Parkinson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-03-17       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.